Deep-dive into SURMOUNT-2 follow-up and extension findings for tirzepatide in type 2 diabetes, covering durability of weight loss, weight regain after discontinuation, and long-term safety signals.
A deep-dive into the SURMOUNT-2 trial design, randomization, estimand framework, and statistical choices that shaped tirzepatide's weight-loss results in type 2 diabetes.
A clear, evidence-based overview of the SURMOUNT-2 trial, which tested tirzepatide for weight loss in adults with type 2 diabetes and obesity. Covers study design, key results, limitations, and clinical relevance.
A deep-dive into the SURMOUNT-2 trial results for tirzepatide in type 2 diabetes, covering primary and secondary endpoints, effect sizes, confidence intervals, response distributions, and the weekly weight-loss trajectory.
Deep-dive into SURMOUNT-2 pre-specified and post-hoc subgroup analyses for tirzepatide in type 2 diabetes: responses by age, sex, BMI, race, and baseline biomarkers.
Health-economic analyses of SURMOUNT-3: cost per QALY for tirzepatide after intensive lifestyle intervention, payer-coverage barriers, list-price vs net-price gaps, and value considerations for patients and clinicians.
Analysis of SURMOUNT-3 long-term follow-up, weight regain patterns after tirzepatide discontinuation, durability of cardiometabolic benefits, and what the trial's design tells us about sustained obesity treatment.
SURMOUNT-3: adults who lost 5%+ weight via 12-week lifestyle program lost 21.1% more with tirzepatide vs 3.3% with placebo over 72 weeks.
Detailed breakdown of the SURMOUNT-3 trial results for tirzepatide after intensive lifestyle intervention, including effect sizes, confidence intervals, secondary endpoints, and response distribution.
Deep-dive into SURMOUNT-4's clinical implications for tirzepatide prescribing: weight regain data, guideline updates, and what the trial means for real-world patients.
A critical analysis of SURMOUNT-4's enrollment biases, follow-up duration, generalizability gaps, statistical caveats, and conflict-of-interest considerations for tirzepatide weight maintenance.
Health-economic analysis of tirzepatide continuation vs discontinuation from SURMOUNT-4, including cost per QALY estimates, payer coverage dynamics, and individual value calculations.
Deep-dive into SURMOUNT-4 follow-up findings on tirzepatide weight regain after discontinuation, durability of effect, and long-term safety signals from the 2024 JAMA trial.
A detailed breakdown of the SURMOUNT-4 trial design, randomized withdrawal methodology, estimand framework, and statistical choices that shaped tirzepatide's weight-regain data.
A granular breakdown of SURMOUNT-4 trial results for tirzepatide, including primary and secondary endpoint data with confidence intervals, weight-regain kinetics on placebo switch, and response distribution across subgroups.
Deep-dive into SURMOUNT-4 pre-specified and post-hoc subgroup analyses for tirzepatide weight maintenance, examining differential responses by age, sex, BMI, race, and baseline biomarkers.
Deep dive into SURPASS-2 follow-up data on tirzepatide vs semaglutide 1 mg in type 2 diabetes, covering durability of A1C and weight effects, post-trial regression, and emerging safety signals.
A plain-English deep dive into the SURPASS-2 trial comparing tirzepatide to semaglutide 1 mg in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
A detailed breakdown of the SURPASS-2 trial results comparing tirzepatide vs semaglutide 1 mg in type 2 diabetes, including effect sizes, confidence intervals, secondary endpoints, and time-course patterns.
Deep-dive into SURPASS-2 pre-specified and post-hoc subgroup analyses comparing tirzepatide vs semaglutide 1 mg across age, sex, BMI, race, and baseline biomarkers in type 2 diabetes.
Deep-dive into the SURPASS-3 open-label extension: durability of tirzepatide's A1C and weight benefits vs insulin degludec over 52 additional weeks, safety signals, and long-term clinical implications.
A detailed methodological breakdown of the SURPASS-3 trial comparing tirzepatide to insulin degludec in type 2 diabetes, covering randomization, blinding, estimand framework, comparator choice, and how each design decision shapes clinical interpretation.
A plain-English deep dive into the SURPASS-3 trial comparing tirzepatide vs insulin degludec in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
A deep-dive into the SUSTAIN-6 trial and how its 26% MACE reduction with semaglutide reshaped prescribing guidelines, cardiology referrals, and GLP-1 use beyond glycemic control in type 2 diabetes.
A critical appraisal of the SUSTAIN-6 cardiovascular outcomes trial for semaglutide, covering enrollment biases, statistical design concerns, generalizability gaps, and what post-publication commentary revealed.
Deep-dive into cost-effectiveness analyses derived from the SUSTAIN-6 cardiovascular outcomes trial of semaglutide, including cost per QALY estimates, payer coverage considerations, and real-world pricing dynamics.
A deep-dive into the SUSTAIN-6 cardiovascular outcomes trial for semaglutide in type 2 diabetes, covering methodology, results, limitations, and clinical implications.
A deep-dive into the SUSTAIN-6 trial results for semaglutide injectable, covering primary MACE endpoint effect sizes, secondary outcomes, subgroup analyses, and the time-course pattern of cardiovascular benefit in type 2 diabetes.
Deep-dive into SUSTAIN-6 pre-specified and post-hoc subgroup analyses for semaglutide injectable, examining differential MACE reduction by age, sex, BMI, baseline HbA1c, renal function, and cardiovascular history in type 2 diabetes.
SUSTAIN-7 found semaglutide beat dulaglutide on A1C and weight loss at every dose over 40 weeks, reshaping GLP-1 prescribing and ADA guidance.
A critical analysis of the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest concerns.
Deep dive into SUSTAIN-7 follow-up and extension data comparing semaglutide vs dulaglutide in type 2 diabetes, examining durability of A1C and weight effects, long-term safety signals, and what the original 40-week trial could not show.
A deep dive into the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering primary and secondary endpoint effect sizes, confidence intervals, time-course data, and response distributions.
SUSTAIN-7 subgroup data: semaglutide beat dulaglutide on A1C and weight in nearly every subgroup, with largest gains in higher baseline BMI and A1C patients.
A deep-dive into the enrollment biases, follow-up constraints, generalizability gaps, and statistical caveats of the landmark 2016 Testosterone Trials in older men.
A deep-dive into the T-Trials' actual effect sizes, confidence intervals, secondary endpoints, and response distribution for testosterone gel in men 65 and older.
Deep-dive into the T-Trials subgroup analyses examining which older men benefited most from testosterone gel by age, BMI, baseline testosterone, and functional status.
How the TRAVERSE trial's cardiovascular safety data for testosterone replacement therapy should reshape prescribing decisions, guideline updates, and patient selection in 2024 and beyond.
Deep dive into TRAVERSE trial follow-up and extension data on testosterone replacement therapy cardiovascular safety in hypogonadal men, including long-term MACE outcomes and emerging safety signals.
A detailed plain-English breakdown of the TRAVERSE trial (2023), the largest randomized controlled trial of testosterone replacement therapy, which tested cardiovascular safety in over 5,200 hypogonadal men with elevated CV risk.
Deep-dive into the TRAVERSE trial's pre-specified and post-hoc subgroup analyses for testosterone gel in hypogonadal men with elevated cardiovascular risk, examining responses by age, BMI, baseline testosterone, race, and comorbidity burden.
A critical examination of the UKPDS 34 trial's enrollment biases, statistical caveats, generalizability gaps, and what post-publication commentary revealed about metformin's landmark evidence base.
Deep-dive into the health-economic modeling behind UKPDS 34, examining metformin's cost per QALY, payer-coverage rationale, and real-world pricing for overweight patients with type 2 diabetes.
A deep-dive into the UKPDS 34 trial design, randomization scheme, endpoint definitions, statistical methods, and how each methodological choice shapes the interpretation of metformin's 32% risk reduction in overweight type 2 diabetes.
A deep-dive into UKPDS 34, the 1998 landmark trial that proved metformin reduces diabetes complications and death in overweight patients with type 2 diabetes, establishing it as first-line therapy worldwide.
Complete breakdown of UKPDS 34 metformin outcomes including effect sizes, confidence intervals, secondary endpoints, and the 10-year time-course pattern in overweight type 2 diabetes.
A deep-dive overview of the Women's Health Initiative estrogen-alone trial (2004), covering methodology, key cardiovascular and breast cancer findings, and what they mean for HRT practice today.
Complete breakdown of the WHI Estrogen-Alone trial results including hazard ratios, confidence intervals, age-stratified subgroups, and the time-course pattern across 7.1 years of follow-up.
How the Women's Health Initiative estrogen-plus-progestin trial reshaped HRT prescribing, which guidelines changed, and what the trial means for patients who don't match its population.
A detailed examination of the WHI E+P trial's enrollment biases, statistical caveats, generalizability gaps, and what subsequent peer commentary revealed about the study that reshaped HRT prescribing for two decades.
Deep-dive into cost-effectiveness analyses from the Women's Health Initiative estrogen-plus-progestin trial, including cost per QALY estimates, payer coverage shifts, and individual value calculations for combined HRT.
Deep dive into the Women's Health Initiative estrogen-plus-progestin trial follow-up and extension studies, covering long-term breast cancer, cardiovascular, and mortality outcomes after stopping combined HRT.
A deep-dive overview of the Women's Health Initiative estrogen-plus-progestin trial, covering methodology, results, limitations, and what the findings mean for HRT prescribing today.
A granular breakdown of the Women's Health Initiative estrogen-plus-progestin trial results, including hazard ratios, confidence intervals, subgroup analyses, and the time-course pattern that reshaped HRT prescribing for two decades.
A clinical review of vaginal estradiol safety for adults aged 30 to 49, covering systemic absorption, breast cancer risk, cardiovascular considerations, and long-term use data.
Find out whether BCBS Federated plans cover vaginal estradiol for genitourinary syndrome of menopause, including formulary tier, prior authorization, step therapy, and appeal options.
A comparison of vaginal estradiol creams, tablets, rings, and suppositories by cost, efficacy, and systemic absorption, with vaginal DHEA and ospemifene as non-estrogen alternatives.
Evidence-based review of vaginal estradiol drug-drug interactions, covering CYP450 metabolism, aromatase inhibitor concerns, anticoagulant effects, and why minimal systemic absorption limits most clinically significant interactions.
Evidence-based monitoring guide for vaginal estradiol use in women aged 65 and older, covering safety labs, systemic absorption, drug interactions, and deprescribing considerations.
Complete guide to Humana coverage for vaginal estradiol including formulary tier placement, prior authorization requirements, step therapy protocols, and how to appeal a denial.